Hormonal
Tirzepatide (5, 10, and 15 mg) achieves stringent glycemic (HbA1c < 5.7% or ≤ 6.5%) and weight loss (≥ 10% or ≥ 15%) targets with a statistically significantly lower cost per responder and lower number needed to treat (NNT) compared to semaglutide 1 mg in patients with type 2 diabetes.
If you have Type 2 Diabetes and are struggling to reach strict blood sugar (HbA1c < 5.7% or ≤ 6.5%) or significant weight loss goals (≥ 10-15%) with metformin, switching to or starting tirzepatide (5-15 mg weekly) is likely more effective and cost-efficient for achieving those specific targets than using semaglutide 1 mg. While tirzepatide has a higher yearly drug price, you are more likely to succeed with it, making it 'cheaper' per successful outcome.
All doses of tirzepatide across composite endpoints (HbA1c < 7.0%, ≤ 6.5%, or < 5.7%/weight loss ≥ 10%/no hypoglycemia) had statistically significantly lower costs per responder and NNTs than semaglutide 1 mg, demonstrating that tirzepatide provides better value for achieving lower HbA1c thresholds and weight loss goals without increasing the risk of hypoglycemia.
Why this rating
Based on a phase 3 randomized clinical trial (SURPASS-2) with a large sample size (n=1,879), though the analysis is a short-term (1-year) economic model rather than long-term clinical outcomes.
Source
Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States
Reema Mody et al. · Diabetes Therapy · 2023
DOI 10.1007/s13300-023-01470-w
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →